공시 • May 27
Sunrest Lifescience Limited to Report Second Half, 2026 Results on May 29, 2026 Sunrest Lifescience Limited announced that they will report second half, 2026 results on May 29, 2026 공시 • May 01
Sunrest Lifescience Limited has withdrawn its Follow-on Equity Offering in the amount of INR 150.192 million. Sunrest Lifescience Limited has withdrawn its Follow-on Equity Offering in the amount of INR 150.192 million.
Security Name: Equity Shares
Security Type: Common Stock
Securities Offered: 4,291,200
Price\Range: INR 35
Transaction Features: Regulation S; Rights Offering Valuation Update With 7 Day Price Move • Mar 23
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to ₹40.00, the stock trades at a trailing P/E ratio of 9.8x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total loss to shareholders of 32% over the past year. Buy Or Sell Opportunity • Mar 16
Now 32% overvalued after recent price rise Over the last 90 days, the stock has risen 12% to ₹48.00. The fair value is estimated to be ₹36.25, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Buy Or Sell Opportunity • Feb 18
Now 21% overvalued Over the last 90 days, the stock has fallen 6.2% to ₹43.80. The fair value is estimated to be ₹36.25, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Valuation Update With 7 Day Price Move • Jan 12
Investor sentiment deteriorates as stock falls 22% After last week's 22% share price decline to ₹35.05, the stock trades at a trailing P/E ratio of 8.5x. Average trailing P/E is 28x in the Pharmaceuticals industry in India. Total loss to shareholders of 34% over the past year. Board Change • Dec 29
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Director Avani Shah was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. 공시 • Nov 12
Sunrest Lifescience Limited to Report First Half, 2026 Results on Nov 13, 2025 Sunrest Lifescience Limited announced that they will report first half, 2026 results on Nov 13, 2025 Valuation Update With 7 Day Price Move • Oct 31
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₹49.00, the stock trades at a trailing P/E ratio of 10.5x. Average trailing P/E is 31x in the Pharmaceuticals industry in India. Total loss to shareholders of 18% over the past year. 공시 • Sep 03
Sunrest Lifescience Limited, Annual General Meeting, Sep 27, 2025 Sunrest Lifescience Limited, Annual General Meeting, Sep 27, 2025, at 15:00 Indian Standard Time. Valuation Update With 7 Day Price Move • Jun 18
Investor sentiment improves as stock rises 22% After last week's 22% share price gain to ₹61.00, the stock trades at a trailing P/E ratio of 13.1x. Average trailing P/E is 32x in the Pharmaceuticals industry in India. Total loss to shareholders of 4.0% over the past year. New Risk • Jun 03
New major risk - Financial position The company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 12% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (12% operating cash flow to total debt). Shares are highly illiquid. Market cap is less than US$10m (₹214.8m market cap, or US$2.51m). Minor Risk Revenue is less than US$5m (₹334m revenue, or US$3.9m). New Risk • Jun 02
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 15% per year over the past 5 years. Market cap is less than US$10m (₹218.9m market cap, or US$2.56m). Minor Risks Latest financial reports are more than 6 months old (reported September 2024 fiscal period end). Revenue is less than US$5m (₹324m revenue, or US$3.8m). 공시 • Dec 19
Sunrest Lifescience Limited Announces Resignation of Nishi Shah as Company Secretary & Compliance Officer Sunrest Lifescience Limited announced that Ms. Nishi Shah has tendered her resignation from the position of Company Secretary & Compliance Officer (Key Managerial Personnel) of the Company vide his letter dated 17th December, 2024. She has decided to move on to pursue opportunities outside the Company. New Risk • Nov 16
New major risk - Revenue and earnings growth Earnings have declined by 15% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 15% per year over the past 5 years. Market cap is less than US$10m (₹236.2m market cap, or US$2.80m). Minor Risk Revenue is less than US$5m (₹324m revenue, or US$3.8m). 공시 • Sep 14
Sunrest Lifescience Limited, Annual General Meeting, Sep 28, 2024 Sunrest Lifescience Limited, Annual General Meeting, Sep 28, 2024, at 15:00 Indian Standard Time. Reported Earnings • May 29
Full year 2024 earnings released: EPS: ₹0.68 (vs ₹6.81 in FY 2023) Full year 2024 results: EPS: ₹0.68 (down from ₹6.81 in FY 2023). Revenue: ₹294.8m (up 20% from FY 2023). Net income: ₹2.26m (down 89% from FY 2023). Profit margin: 0.8% (down from 8.3% in FY 2023). The decrease in margin was driven by higher expenses. Valuation Update With 7 Day Price Move • May 16
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₹75.00, the stock trades at a trailing P/E ratio of 15.8x. Average trailing P/E is 34x in the Pharmaceuticals industry in India. New Risk • May 15
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.7% average weekly change). Revenue has declined by 8.4% over the past year. High level of non-cash earnings (21% accrual ratio). Market cap is less than US$10m (₹317.5m market cap, or US$3.80m). Minor Risks High level of debt (54% net debt to equity). Latest financial reports are more than 6 months old (reported March 2023 fiscal period end). Revenue is less than US$5m (₹246m revenue, or US$3.0m). New Risk • May 05
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Revenue has declined by 8.4% over the past year. High level of non-cash earnings (21% accrual ratio). Market cap is less than US$10m (₹301.5m market cap, or US$3.62m). Minor Risks High level of debt (54% net debt to equity). Share price has been volatile over the past 3 months (8.4% average weekly change). Revenue is less than US$5m (₹246m revenue, or US$3.0m). Board Change • Nov 18
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 5 non-independent directors. Independent Director Avani Shah was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.